Wilmer Cutler Pickering Hale and Dorr LLP advised the underwriters on the deal.
NeuBase Therapeutics, Inc. (Nasdaq: NBSE), (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock (inclusive of 1,200,000 shares that were sold pursuant to the underwriters’ full exercise of their option to purchase additional shares of NeuBase’s common stock), at a price to the public of $5.00 per share, generating gross proceeds of $46.0 million before deducting the underwriting discounts and commissions and offering expenses payable by NeuBase. NeuBase intends to use the net proceeds from the offering for general corporate purposes, working capital and development of its product candidates and pipeline expansion.
RBC Capital Markets, Oppenheimer & Co. Inc. and Chardan acted as the joint book-running managers for the offering, and National Securities Corporation acted as co-manager for the offering.
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease.
The WilmerHale team advising the underwriters consisted of Glenn Pollner (Picture), Colleen Superko, Stephanie Leopold and Gerard Fischetti.
Involved fees earner: Gerard Fischetti – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Stephanie Leopold – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Glenn Pollner – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Colleen Superko – WilmerHaleWilmer Cutler Pickering Hale and Dorr;
Law Firms: WilmerHaleWilmer Cutler Pickering Hale and Dorr;